Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Gross Profit data on record, last reported at $140.7 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 128.91% year-over-year to $140.7 million; the TTM value through Dec 2025 reached $420.7 million, up 147.27%, while the annual FY2025 figure was $420.7 million, 147.27% up from the prior year.
  • Gross Profit reached $140.7 million in Q4 2025 per TARS's latest filing, up from $110.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $140.7 million in Q4 2025 and bottomed at $362000.0 in Q4 2021.
  • Average Gross Profit over 5 years is $38.1 million, with a median of $23.6 million recorded in 2021.
  • Peak YoY movement for Gross Profit: plummeted 98.43% in 2022, then skyrocketed 2903.75% in 2024.
  • A 5-year view of Gross Profit shows it stood at $362000.0 in 2021, then surged by 2551.93% to $9.6 million in 2022, then grew by 23.54% to $11.9 million in 2023, then soared by 418.4% to $61.5 million in 2024, then skyrocketed by 128.91% to $140.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $140.7 million in Q4 2025, $110.4 million in Q3 2025, and $96.4 million in Q2 2025.